| |
Puerto Rico offers top-notch talent, smart tax incentives & a robust supply chain, making it a bioscience powerhouse. With the highest concentration of pharma & medical device talent in the U.S., & extensive tax benefits, it’s the top destination for innovation. Visit our booth at BIO to learn more.
|
|
Today’s Big NewsJun 5, 2024 |
| By Fraiser Kansteiner Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5 billion in costs by the end of 2025, a company spokesperson said over email. |
|
|
|
By Annalee Armstrong Lykos Therapeutics’ efforts to get the first ever MDMA treatment approved for post-traumatic stress disorder suffered a crushing blow yesterday, when an FDA advisory committee voted against recommending approval. |
By Fraiser Kansteiner Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease. Now, the company is laying out the fine details. |
By Annalee Armstrong Viking Therapeutics is pulling up some extra long boats full of reasons its metabolic dysfunction associated steatohepatitis (MASH) drug could be a winner, but executives were mum on exactly what the med’s future will be given the competitive landscape. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now.
|
|
By Ben Adams AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. |
By Conor Hale According to the company, the dedicated Bluetooth connection can deliver data and blood sugar alerts straight to a person’s wrist, such as during a workout, for example. |
By Kevin Dunleavy After 23 years at Eli Lilly, including the last three as its chief financial officer, Anat Ashkenazi is leaving to take the same role at a powerhouse company in a different industry. Ashkenazi, 51, has been hired by tech giant Alphabet—the parent company of Google—to become its CFO. |
By Andrea Park When it resumed advertisements of Wegovy on U.S. TVs earlier this year, Novo Nordisk focused largely on the more emotional effects of the weight loss drug. Now, however, the Big Pharma has put the spotlight back on Wegovy’s physical effects. |
By Gabrielle Masson Digital business cards. Gilead’s virtual reality ride. Soccer’s champions league final. A motorcycle brigade. This year’s American Society of Clinical Oncology conference in Chicago marked a return to its pre-pandemic heyday. |
By Nick Paul Taylor The multiple myeloma market is booming. Bloomberg Intelligence (BI) forecasts sales will hit $33 billion in 2030, up almost $10 billion on last year, as Johnson & Johnson wrestles control of the blood cancer market from Bristol Myers Squibb. |
By Zoey Becker The drug reduced the risk of immunoglobulin G4-related disease flares by 87% over placebo in a phase 3 study of 135 patients. The chronic disease currently has no approved treatments outside of steroids. |
By Nick Paul Taylor Gilead shared more data on its $4.3 billion, near-approval liver disease prospect Wednesday, linking the candidate to sustained improvements across two years of treatment. |
By Conor Hale It’s all systems go for Moon Surgical with a new FDA green light for its Maestro robotic laparoscopy platform. |
By Andrea Park In the latest brand consolidation move under the Inizio umbrella, the company’s Inizio Engage unit has combined two of its experiential design-focused agencies. |
Fierce podcastsDon’t miss an episode |
| In this week's episode of "The Top Line," two journalists from the Fierce Biotech team share key insights from their four-part series on the challenges and breakthroughs in cell therapy. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us for a one-hour discussion on oral cyclic peptide drug development. Learn about key breakthroughs that demonstrate results. Register now.
|
|
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
